The Wolverine stack—BPC-157 for building new blood vessels, TB-500 for moving repair cells to the injury—targets the early stages of tissue healing. But healing does not stop there. After new blood vessels form and repair cells arrive, the body still needs to remodel that fresh tissue into something strong enough to bear load. Collagen fibers need to be cross-linked. The structural scaffold of the tissue—what scientists call the extracellular matrix—needs to be reorganized. This remodeling phase is where the GLOW protocol claims its rationale.

GLOW adds GHK-Cu—a naturally occurring copper peptide—to the Wolverine base. The logic: BPC-157 builds the blood supply, TB-500 recruits the repair workforce, and GHK-Cu supplies the copper that enzymes need to strengthen the repaired tissue. Three compounds targeting three stages of healing, one protocol. It has become one of the most discussed peptide stacks in self-experimentation communities—and understanding whether GHK-Cu delivers real benefit requires looking carefully at what the evidence actually supports.

Whether the logic justifies the additional compound, cost, and complexity depends on GHK-Cu’s evidence profile—and that profile is more complicated than most sources acknowledge.

What Is the Glow Stack

BPC-157

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from human gastric juice. Its primary mechanism is VEGF-mediated angiogenesis—stimulating new blood vessel formation at injury sites. Peptidings assigns BPC-157 a Tier 3 (Pilot/Limited Human Data) rating based on a small number of human trials alongside extensive preclinical evidence. BPC-157 is not FDA-approved and is WADA-prohibited.

TB-500

TB-500 (Thymosin Beta-4 fragment) drives cell migration through actin sequestration, recruiting repair cells to injury sites. Peptidings assigns TB-500 a Tier 4 (Preclinical Only) rating—no published human trials exist for injectable TB-500 in musculoskeletal indications. TB-500 is not FDA-approved and is WADA-prohibited.

GHK-Cu

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is an endogenous tripeptide whose plasma levels decline with age. It delivers copper to enzymatic systems (lysyl oxidase for collagen cross-linking, superoxide dismutase for antioxidant defense), stimulates collagen and elastin synthesis, and modulates expression of over 4,000 human genes in genomic studies. Peptidings assigns GHK-Cu an “It’s Complicated” tier because topical GHK-Cu has decades of human evidence while injectable GHK-Cu has essentially none. FDA Category 1 for 503A compounding (non-injectable routes only). WADA: not prohibited.

Why People Combine BPC-157, TB-500, and GHK-Cu

As established in the Wolverine guide, the BPC-157 + TB-500 pairing is additive—two different mechanisms, no demonstrated synergy. Adding GHK-Cu does not change that assessment. It adds a third distinct mechanism (copper-dependent ECM remodeling) operating through a third molecular pathway (lysyl oxidase activation, collagen gene expression). There is no published evidence that GHK-Cu potentiates either BPC-157 or TB-500, or vice versa.

The GLOW protocol is therefore three parallel interventions: angiogenesis, cell migration, and matrix remodeling. 1+1+1=3, not 4. The value proposition rests on whether each compound individually contributes meaningfully—not on any amplification between them.

Compound	Primary Mechanism	Repair Phase	Evidence Tier
BPC-157	VEGF-mediated angiogenesis	Early (vascular)	Pilot / Limited Human Data
TB-500	Actin sequestration / cell migration	Early–mid (cellular)	Preclinical Only
GHK-Cu	Copper delivery / collagen cross-linking / ECM gene expression	Late (remodeling)	It’s Complicated

One additional consideration: GHK-Cu also has documented angiogenic properties, adding a third source of pro-angiogenic signaling to a stack that already includes two (BPC-157 and TB-500). This is relevant to the risk profile discussed in the Safety section.

How the Mechanism Works (and Where It’s Theoretical)

BPC-157

BPC-157’s primary mechanism is VEGF upregulation—stimulating vascular endothelial growth factor to promote new blood vessel formation at injury sites. In preclinical models, BPC-157 accelerates angiogenesis in tendons, ligaments, muscles, and the GI tract. The mechanism is well-characterized in rodent models but not confirmed at the tissue level in human injectable studies.

TB-500

TB-500 sequesters G-actin monomers, shifting the equilibrium toward polymerized F-actin at cell leading edges. This promotes cell migration—the process by which repair cells travel to an injury site. In rodent wound-healing models, TB-500 accelerates fibroblast and endothelial cell migration. TB-500 also has independent angiogenic properties, contributing a second pro-vascular signal alongside BPC-157.

GHK-Cu

GHK-Cu delivers copper ions to lysyl oxidase—the enzyme that cross-links collagen fibers into mechanically mature tissue. It also directly stimulates collagen I, collagen III, and elastin gene expression, and modulates metalloproteinase activity (the enzymes that remodel the extracellular matrix). In genomic studies, GHK-Cu influenced expression of over 4,000 genes at in vitro concentrations—though whether injectable doses achieve comparable tissue concentrations is unknown.

The Combination: Theoretical, Untested

The proposed cascade—BPC-157 builds blood vessels, TB-500 recruits repair cells, GHK-Cu matures the repaired tissue—maps logically onto the three phases of wound healing (inflammation/vascularization, proliferation/migration, remodeling). However, this is a narrative assembled from three independent bodies of preclinical research. No study has tested whether these three mechanisms actually coordinate when the compounds are co-administered. The synergy narrative is biological storytelling, not demonstrated pharmacology.

What the Evidence Actually Shows

BPC-157 — Pilot / Limited Human Data

BPC-157 has the strongest human evidence base of the three compounds, though it remains limited. A small number of human trials exist for oral BPC-157 in inflammatory bowel disease. For injectable use in musculoskeletal indications—the relevant route for the GLOW protocol—evidence remains primarily preclinical. Dozens of rodent studies demonstrate accelerated healing of tendons, ligaments, muscles, and bones, but translation to human injectable use at self-experimentation doses is unvalidated.

TB-500 — Preclinical Only

TB-500 has no published human trials for injectable musculoskeletal use. All evidence comes from preclinical models—rodent wound healing, cardiac repair in animal models, and cell culture migration assays. The compound is widely used in veterinary medicine (equine tendon repair) under the name Tβ4, but veterinary dosing and pharmacokinetics differ substantially from human self-experimentation protocols.

GHK-Cu — It’s Complicated

This is where the GLOW stack’s evidence picture becomes uniquely complicated. Topical GHK-Cu has decades of human evidence—cosmetic formulations for skin aging, wound healing studies on surgical scars and burns, photoprotection research. GHK-Cu is one of the most commercially available peptide ingredients in skincare. If we were evaluating topical GHK-Cu for a skin-surface protocol, the evidence base would be substantially stronger than either BPC-157 or TB-500. But the GLOW protocol uses injectable GHK-Cu, and for subcutaneous injection there are zero published human trials at any dose in any indication. Citing topical wound healing data to justify injectable use is a category error that pervades the community literature on this compound.

The Stack as a Combination

No study has tested BPC-157 + TB-500 + GHK-Cu, or any two-compound subset involving GHK-Cu, in any model—preclinical or clinical. The combination evidence base is nonexistent.

Claims vs. Evidence

#	Claim	What the Evidence Shows	Verdict
1	“GHK-Cu completes the healing trifecta”	GHK-Cu targets a genuinely distinct mechanism (ECM remodeling). But “completing” the trifecta assumes the first two compounds work as intended at self-experimentation doses—an assumption that is itself unvalidated. You are stacking an unproven compound onto two unproven compounds.	Preclinical Only
2	“GHK-Cu has decades of human safety data”	For topical application—yes. For injectable systemic use—no. The safety profile of a topical compound cannot be transferred to subcutaneous injection. Different route, different systemic exposure, different risk profile.	Mixed Evidence
3	“GHK-Cu modulates 4,000 genes—it does everything”	Genomic studies reported GHK-Cu influencing ~4,000 genes at in vitro concentrations. Whether injectable doses achieve the same tissue concentrations is unknown. Broad gene modulation is an in vitro observation, not a validated in vivo effect at subcutaneous doses.	Preclinical Only
4	“GLOW is better than Wolverine for deep tissue injuries”	No comparison exists—anecdotal, preclinical, or clinical. The addition of an ECM-remodeling compound is mechanistically logical for late-phase tissue maturation, but whether injectable GHK-Cu reaches deep tissue at therapeutic concentrations is unknown.	Unsupported

Safety, Risks, and Unknowns

The Wolverine guide covers the base risks of this protocol category—the angiogenesis concern, pharmacokinetic unknowns, and quality risks. Adding GHK-Cu introduces additional considerations.

Triple Angiogenic Signaling

The Wolverine guide flags the concern of stacking two pro-angiogenic compounds. GLOW makes it three. GHK-Cu has documented angiogenic activity in preclinical models—stimulating endothelial cell proliferation and new vessel formation. Combined with BPC-157’s VEGF pathway and TB-500’s actin-dependent angiogenesis, the GLOW protocol delivers pro-angiogenic signaling from three distinct molecular pathways simultaneously. For injury healing, this may be the intended effect. For individuals with occult vascular-dependent pathology, the cumulative signal is the concern. This risk intensifies, not merely persists, when moving from two compounds to three.

Copper Accumulation

GHK-Cu delivers exogenous copper. The body tightly regulates copper homeostasis—ceruloplasmin, metallothionein, and ATP7A/ATP7B transporters maintain plasma and tissue copper levels within a narrow range. At self-experimentation doses (1–2 mg GHK-Cu per day), acute copper toxicity is unlikely. However, individuals with undiagnosed Wilson disease, those taking copper supplements, or those with liver impairment should be aware that exogenous copper delivery, even in small amounts, adds to total body copper burden.

Compounding Complexity

Three compounds means three vials, three reconstitutions, three to four injections per day, three sets of COAs to verify, and three potential sources of quality or contamination issues. Each additional compound adds a multiplicative variable—not just additive. If something goes wrong, isolating the cause becomes more difficult.

The Attribution Problem

If you experience an adverse effect on a three-compound protocol, you have no way to determine which compound is responsible without discontinuing all three and reintroducing them individually. This is not a minor inconvenience—it is a fundamental limitation of multi-compound protocols that increases linearly with each added compound. With Wolverine (two compounds), you have two suspects. With GLOW (three compounds), you have three suspects and six possible interaction pairs.

Legal and Regulatory Status

BPC-157: Not FDA-approved for any indication. Classified as a research chemical. WADA-prohibited under S0 (Non-Approved Substances). Available through research-chemical vendors and some compounding pharmacies.

TB-500: Not FDA-approved for human use. WADA-prohibited under S2 (Peptide Hormones). Available through research-chemical vendors. Used in veterinary medicine under the name Tβ4.

GHK-Cu: FDA Category 1 for 503A compounding—non-injectable routes only. Injectable forms are restricted. Widely available in topical cosmetic products without prescription. WADA: not prohibited. This creates an unusual regulatory profile: the compound is commercially legal as a topical but restricted as an injectable.

The stack combined: Using the GLOW protocol means administering two WADA-prohibited compounds (BPC-157, TB-500) and one injectable-restricted compound (GHK-Cu) via subcutaneous injection. All three are sourced from unregulated supply chains when obtained outside of compounding pharmacies.

Dosing — Published Research and Community Protocols

Published Research Dosing

No published research has established optimal dosing for any of the three GLOW compounds via subcutaneous injection for musculoskeletal indications. BPC-157’s limited human trials used oral administration for GI indications. TB-500 has no human dosing data. GHK-Cu’s human studies used topical application, not injection. All injectable dosing below is community-derived.

Community Self-experimentation Protocols

The GLOW protocol builds on the Wolverine dosing framework by adding GHK-Cu as a third compound. BPC-157 and TB-500 dosing follows the Wolverine protocol unchanged.

Parameter	BPC-157	TB-500	GHK-Cu (Injectable)	GHK-Cu (Topical)
Typical dose	250–500 mcg/day	2–2.5 mg 2×/week	1–2 mg/day	1–3% serum applied topically
Route	Subcutaneous	Subcutaneous	Subcutaneous	Topical over injury site
Frequency	1–2× daily	2×/week (loading), 1×/week (maintenance)	1× daily	1–2× daily
Duration	4–8 weeks	4–8 weeks	4–8 weeks concurrent	Duration of wound healing
Evidence for this route	Preclinical (injectable)	Preclinical only	Preclinical only	Human data (cosmetic/wound healing)

The topical option: For surface-level injuries—surgical incisions, skin wounds, burns—topical GHK-Cu has the stronger evidence base and avoids the injectable evidence gap entirely. Some community protocols use both routes simultaneously. For deep tissue injuries (tendons, ligaments, muscle bellies), topical application is unlikely to deliver meaningful concentrations to the target tissue.

Multi-peptide Vial Reality

Do not mix GHK-Cu with other peptides in the same vial or syringe. The copper moiety may catalyze oxidation of methionine, cysteine, tryptophan, or tyrosine residues in other peptides, producing degradation products with unknown activity. Separate vial, separate syringe, separate injection site for each compound.

Research-chemical vendors sell pre-lyophilized “GLOW blend” vials containing all three compounds co-lyophilized. These products raise additional concerns: copper-mediated degradation during storage, unknown stability profiles for the combination, and the impossibility of verifying that each compound is present at its labeled concentration without independent third-party testing. CoA verification for multi-compound blends is more complex than for single-compound vials—each compound needs its own assay.

Reconstitution and storage: GHK-Cu is supplied as a lyophilized powder. Reconstitute with bacteriostatic water, store at 2–8°C (35–46°F), use within 28 days.

Frequently Asked Questions

Summary

Three compounds, zero combination data. The GLOW stack targets three real stages of tissue healing—building blood vessels, moving repair cells, and strengthening the repaired tissue. The logic makes sense. But nobody has tested whether the three compounds actually work together, in any species.

GHK-Cu’s reputation outruns its injectable evidence. GHK-Cu has strong human data as a skin cream and almost none as an injection. If you are adding injectable GHK-Cu to the GLOW protocol, you are working with less evidence than GHK-Cu’s name recognition would suggest. The strength of the topical data creates a false sense of confidence that does not extend to the injectable route.

The topical route deserves serious consideration. For injuries at or near the skin surface, topical GHK-Cu alongside the injectable Wolverine base may be the most evidence-defensible version of the GLOW protocol—it uses the route that actually has human data behind it.

Three compounds amplify every risk. Three sources of blood-vessel-growth signaling. Copper accumulation. The impossibility of identifying which compound caused a side effect. Three vials, three reconstitutions, three injection sites. Each additional compound does not just add complexity—it multiplies it.

Add GHK-Cu last, not first. If you proceed, start with the Wolverine base for one to two weeks before introducing GHK-Cu. Consider the topical route first. Do not mix compounds in the same vial. Maintain written logs and baseline bloodwork.

For the full evidence assessment of each individual compound, see BPC-157, TB-500, and GHK-Cu. For the Wolverine base protocol, see the Wolverine Stack guide.

References and Related Content

Selected References

1. Pickart, L., Vasquez-Soltero, J. M., & Margolina, A. (2015). “GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.” BioMed Research International, 2015, 648108. PubMed
2. Pickart, L., Vasquez-Soltero, J. M., & Margolina, A. (2012). “GHK and DNA: Resetting the Human Genome to Health.” BioMed Research International, 2012, 153626. PubMed
3. Siméon, A., Wegrowski, Y., Bontemps, Y., & Maquart, F. X. (2000). “Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu(2+).” Journal of Investigative Dermatology, 115(6), 962–968. PubMed
4. Cerovecki, T., et al. (2010). “Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat.” Journal of Orthopaedic Research, 28(9), 1155–1161. PubMed
5. Malinda, K. M., et al. (1999). “Thymosin beta4 accelerates wound healing.” Journal of Investigative Dermatology, 113(3), 364–368. PubMed
6. Maquart, F. X., et al. (1988). “Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+.” FEBS Letters, 238(2), 343–346. PubMed

Related Content on Peptidings

– The Wolverine Stack: BPC-157 and TB-500 — Prerequisite reading. The GLOW protocol builds on this foundation.

– The KLOW Protocol: Adding KPV to the GLOW Stack — The four-compound extension.

– BPC-157 — Full compound article with evidence assessment.

– TB-500 — Full compound article with evidence assessment.

– GHK-Cu — Full compound article with evidence assessment.

– Bacteriostatic Water — Reconstitution guide for lyophilized peptides.

– Injection Site Rotation — Multi-compound injection site management.